IL2 and glioblastoma: It has been reported that glioblastoma (GBM) CSCs are vulnerable to IL-2/IL-15-activated NK cells due to their expression of cytotoxicity receptors and ligands (i.e., PVR and Nectin-2) and the reduction of MHC-I molecules on their surface [81].